<table stylecode="Noautorules" width="650" xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<tfoot>
<tr>
<td colspan="2">
<sup>a </sup>Should be administered at least 4 hours prior to WELCHOL</td>
</tr>
<tr>
<td colspan="2">
<sup>b </sup>No significant alteration of warfarin drug levels with warfarin and WELCHOL coadministration in an <content stylecode="italics">in vivo</content> study which did not evaluate warfarin pharmacodynamics (INR).  <content stylecode="italics">[See Post-marketing Experience (<linkhtml href="#s062">6.2</linkhtml>)]</content>
</td>
</tr>
<tr>
<td colspan="2">
<content stylecode="italics">
<sup>c </sup>
</content>Cyclosporine levels should be monitored and, based on theoretical grounds, cyclosporine should be administered at least 4 hours prior to WELCHOL.</td>
</tr>
<tr>
<td colspan="2">
<sup>d </sup>Patients receiving concomitant metformin ER and colesevelam should be monitored for clinical response as is usual for the use of anti-diabetes drugs.</td>
</tr>
</tfoot>
<tbody>
<tr>
<td align="center" colspan="2">
<content stylecode="bold">Table 4 Drugs Tested in <content stylecode="italics">In Vitro</content> Binding or <content stylecode="italics">In Vivo</content> Drug Interaction Testing or With Post-Marketing Reports</content>
</td>
</tr>
<tr>
<td stylecode="Toprule Botrule Lrule Rrule" valign="top">Drugs with a known interaction with colesevelam:<br/>Decrease in exposure of coadministered drug</td>
<td stylecode="Toprule Botrule Lrule Rrule" valign="top">cyclosporine<sup>c</sup>, glimepiride<sup>a</sup>, glipizide<sup>a</sup>, glyburide<sup>a</sup>,<br/>levothyroxine<sup>a</sup>, olmesartan medoxomil<sup>a</sup>, and oral<br/>contraceptives containing ethinyl estradiol and<br/>norethindrone<sup>a</sup>
</td>
</tr>
<tr>
<td stylecode="Toprule Botrule Lrule Rrule" valign="top">Drugs with a known interaction with colesevelam:<br/>Increase in exposure of coadministered drug</td>
<td stylecode="Toprule Botrule Lrule Rrule" valign="top">metformin extended release (ER)<sup>d</sup>
</td>
</tr>
<tr>
<td stylecode="Toprule Botrule Lrule Rrule" valign="top">Drug(s) with postmarketing reports consistent with<br/>potential drug-drug interactions when<br/>coadministered with WELCHOL </td>
<td stylecode="Toprule Botrule Lrule Rrule" valign="top">phenytoin<sup>a</sup>, warfarin<sup>b</sup>
</td>
</tr>
<tr>
<td stylecode="Toprule Botrule Lrule Rrule" valign="top">Drugs that do not interact with colesevelam based<br/>on <content stylecode="italics">in vitro</content> or <content stylecode="italics">in vivo</content> testing </td>
<td stylecode="Toprule Botrule Lrule Rrule" valign="top">aspirin, atenolol, cephalexin, ciprofloxacin,<br/>digoxin, enalapril, fenofibrate, lovastatin,<br/>metformin, metoprolol, phenytoin<sup>a</sup>, pioglitazone,<br/>rosiglitazone, quinidine, repaglinide, sitagliptin,<br/>valproic acid, verapamil, warfarin<sup>b</sup>
</td>
</tr>
</tbody>
</table>